Výsledky vyhľadávania - "Pivot, Xavier"

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer Autor Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia V, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J. Thaddeus, Pivot, Xavier, Sondhi, Manu, Wang, Yingbo, Chakravartty, Arunava, Rodriguez-Lorenc, Karen, Taran, Tetiana, Jerusalem, Guy

“…An earlier report documented significant improvement in progression-free survival among patients with metastatic breast cancer treated with fulvestrant and a…”
Získať plný text

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 Autor Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia Val, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J Thaddeus, Pivot, Xavier, Vidam, Gena, Wang, Yingbo, Rodriguez Lorenc, Karen, Miller, Michelle, Taran, Tetiana, Jerusalem, Guy

“…Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative…”
Zistit podrobnosti o prístupe

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer Autor Miles, David W, Chan, Arlene, Dirix, Luc Y, Cortés, Javier, Pivot, Xavier, Tomczak, Piotr, Delozier, Thierry, Sohn, Joo Hyuk, Provencher, Louise, Puglisi, Fabio, Harbeck, Nadia, Steger, Guenther G, Schneeweiss, Andreas, Wardley, Andrew M, Chlistalla, Andreas, Romieu, Gilles

“…The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2)…”
Zistit podrobnosti o prístupe

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer Autor Johnston, Stephen, Pippen, Jr, John, Pivot, Xavier, Lichinitser, Mikhail, Sadeghi, Saeed, Dieras, Veronique, Gomez, Henry Leonidas, Romieu, Gilles, Manikhas, Alexey, Kennedy, M John, Press, Michael F, Maltzman, Julie, Florance, Allison, O'Rourke, Lisa, Oliva, Cristina, Stein, Steven, Pegram, Mark

“…Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated…”
Zistit podrobnosti o prístupe

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE Autor Perez, Edith A., Barrios, Carlos, Eiermann, Wolfgang, Toi, Masakazu, Im, Young‐Hyuck, Conte, Pierfranco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B., Burris, Howard A., Petersen, Jennifer A., De Haas, Sanne, Hoersch, Silke, Patre, Monika, Ellis, Paul Anthony

“…Background In the phase 3 MARIANNE trial, trastuzumab emtansine (T‐DM1) with or without pertuzumab showed noninferior progression‐free survival and better…”
Získať plný text

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis Autor Paracha, Noman, Reyes, Adriana, Diéras, Véronique, Krop, Ian, Pivot, Xavier, Urruticoechea, Ander

“…Purpose In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments…”
Získať plný text

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer Autor Perez, Edith A., de Haas, Sanne Lysbet, Eiermann, Wolfgang, Barrios, Carlos H., Toi, Masakazu, Im, Young-Hyuck, Conte, Pier Franco, Martin, Miguel, Pienkowski, Tadeusz, Pivot, Xavier B., Burris, Howard A., Stanzel, Sven, Patre, Monika, Ellis, Paul Anthony

“…Background The phase III EMILIA and TH3RESA trials demonstrated clinical benefits of trastuzumab emtansine (T-DM1) therapy in patients with previously treated…”
Získať plný text

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer Autor Gianni, Luca, Romieu, Gilles H, Lichinitser, Michail, Serrano, Sergio V, Mansutti, Mauro, Pivot, Xavier, Mariani, Paola, Andre, Fabrice, Chan, Arlene, Lipatov, Oleg, Chan, Stephen, Wardley, Andrew, Greil, Richard, Moore, Nicola, Prot, Sylvie, Pallaud, Celine, Semiglazov, Vladimir

“…PURPOSE The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic…”
Zistit podrobnosti o prístupe

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine Autor Perez, Edith A, Lerzo, Guillermo, Pivot, Xavier, Thomas, Eva, Vahdat, Linda, Bosserman, Linda, Viens, Patrice, Cai, Can, Mullaney, Brian, Peck, Ronald, Hortobagyi, Gabriel N

“…To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer (MBC) resistant to anthracycline, taxane, and capecitabine, in…”
Zistit podrobnosti o prístupe

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab Autor Marty, Michel, Pivot, Xavier

“…The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of…”
Získať plný text

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial Autor Pivot, Xavier, Romieu, Gilles, Debled, Marc, Pierga, Jean-Yves, Kerbrat, Pierre, Bachelot, Thomas, Lortholary, Alain, Espié, Marc, Fumoleau, Pierre, Serin, Daniel, Jacquin, Jean-Philippe, Jouannaud, Christelle, Rios, Maria, Abadie-Lacourtoisie, Sophie, Tubiana-Mathieu, Nicole, Cany, Laurent, Catala, Stéphanie, Khayat, David, Pauporté, Iris, Kramar, Andrew

“…Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer. However, the optimum…”
Získať plný text

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial Autor Cameron, David, Brown, Julia, Dent, Rebecca, Jackisch, Christian, Mackey, John, Pivot, Xavier, Steger, Guenther G, Suter, Thomas M, Toi, Masakazu, Parmar, Mahesh, Laeufle, Rita, Im, Young-Hyuck, Romieu, Gilles, Harvey, Vernon, Lipatov, Oleg, Pienkowski, Tadeusz, Cottu, Paul, Chan, Arlene, Im, Seock-Ah, Hall, Peter S, Bubuteishvili-Pacaud, Lida, Henschel, Volkmar, Deurloo, Regula J, Pallaud, Celine, Bell, Richard

“…The addition of bevacizumab to chemotherapy improves progression-free survival in metastatic breast cancer and pathological complete response rates in the…”
Získať plný text

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study Autor Pivot, Xavier, Gligorov, Joseph, Müller, Volkmar, Barrett-Lee, Peter, Verma, Sunil, Knoop, Ann, Curigliano, Giuseppe, Semiglazov, Vladimir, López-Vivanco, Guillermo, Jenkins, Valerie, Scotto, Nana, Osborne, Stuart, Fallowfield, Lesley

“…Subcutaneous trastuzumab has shown non-inferior efficacy and a similar pharmacokinetic and safety profile when compared with intravenous trastuzumab in…”
Získať plný text

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment Autor Thomas, Eva S, Gomez, Henry L, Li, Rubi K, Chung, Hyun-Cheol, Fein, Luis E, Chan, Valorie F, Jassem, Jacek, Pivot, Xavier B, Klimovsky, Judith V, de Mendoza, Fernando Hurtado, Xu, Binghe, Campone, Mario, Lerzo, Guillermo L, Peck, Ronald A, Mukhopadhyay, Pralay, Vahdat, Linda T, Roché, Henri H

“…Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has single-agent…”
Zistit podrobnosti o prístupe

Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice Autor Mouillet, Guillaume, Falcoz, Antoine, Fritzsch, Joëlle, Almotlak, Hamadi, Jacoulet, Pascale, Pivot, Xavier, Villanueva, Cristian, Mansi, Laura, Kim, Stefano, Curtit, Elsa, Meneveau, Nathalie, Adotevi, Olivier, Jary, Marine, Eberst, Guillaume, Vienot, Angelique, Calcagno, Fabien, Pozet, Astrid, Djoumakh, Oumelkheir, Borg, Christophe, Westeel, Virginie, Anota, Amélie, Paget-Bailly, Sophie

“…Introduction Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical care with real-time feedback to physicians could…”
Získať plný text

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer Autor Cortés, Javier, Fumoleau, Pierre, Bianchi, Giulia Valeria, Petrella, Teresa M, Gelmon, Karen, Pivot, Xavier, Verma, Shailendra, Albanell, Joan, Conte, Pierfranco, Lluch, Ana, Salvagni, Stefania, Servent, Veronique, Gianni, Luca, Scaltriti, Maurizio, Ross, Graham A, Dixon, Joanna, Szado, Tania, Baselga, José

“…The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2)…”
Zistit podrobnosti o prístupe

Influence of pneumatic transportation on the stability of monoclonal antibodies Autor Coliat, Pierre, Erb, Stéphane, Diemer, Hélène, Karouby, Dan, Martin, Tristan, Banerjee, Mainak, Zhu, Chen, Demarchi, Martin, Cianférani, Sarah, Detappe, Alexandre, Pivot, Xavier

“…Pneumatic transportation systems (PTS) were recently proposed as a method to carry ready-for-injection diluted monoclonal antibodies (mAbs) from the pharmacy…”
Získať plný text

Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients Autor Paquette, Brice, Kalbacher, Elsa, Mercier, Frédéric, Lakkis, Zaher, Doussot, Alexandre, Turco, Célia, Caputo, Edda, Pili-Floury, Sébastien, Royer, Bernard, Mansi, Laura, Delroeux, Delphine, Demarchi, Martin, Pivot, Xavier, Chauffert, Bruno, Clement, Elise, Heyd, Bruno

“…Introduction Ovarian cancer (OC) is the most lethal gynecological cancer. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy…”
Získať plný text

Incidental axillary dose delivery to axillary lymph node levels I–III by different techniques of whole-breast irradiation: a systematic literature review Autor Schmitt, Martin, Pin, Yvan, Pflumio, Carole, Mathelin, Carole, Pivot, Xavier, Noel, Georges

“…Background and objective In breast cancer treatment, radiotherapy is an essential component for locoregional management. Axillary recurrence in patients with…”
Získať plný text

Persistent taxane‐induced neuropathy in elderly patients treated for localized breast cancer Autor Pabst, Lucile, Velten, Michel, Fischbach, Cathie, Kalish, Michal, Pflumio, Carole, Pivot, Xavier, Petit, Thierry

“…Breast cancer is the most common cancer among women. Localized breast cancer treatments involve taxanes which are often responsible for acute peripheral…”
Získať plný text